Ari Nowacek is a co-founder and Senior Vice President of Corporate Development of City Therapeutics. Dr. Nowacek brings a strong track record of applying his expertise to help create and scale companies.

Dr. Nowacek has been a member of ARCH Venture Partners since 2016 and is a partner at the fund. While at ARCH, he has led company creation and placed investments across numerous fields including oncology, renal disease, autoimmune, immunology, gene therapy, coagulation, and brain-computer interface.

Dr. Nowacek holds B.S. degrees in Biology and Psychology from the University of Indiana-Bloomington. He also holds an M.D. and Ph.D. from the University of Nebraska Medical Center and an MBA from the University of Nebraska-Omaha. He subsequently completed a medical residency in Pathology and postdoctoral research at the University of Chicago and Massachusetts General Hospital.